ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant Melanoma

Rhea-AI Summary

Innovent Biologics presented breakthrough Phase 1/2 clinical data for IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, at ASCO 2025. The drug showed promising results in treating immunotherapy-pretreated advanced melanoma, particularly in 'cold tumor' subtypes. Among 31 patients treated with 1 mg/kg Q2W, the confirmed objective response rate was 23.3%, with disease control rate reaching 76.7%. The median progression-free survival was 5.7 months, and overall survival was 14.8 months, with a 61.5% 12-month survival rate. IBI363 demonstrated a manageable safety profile, with mostly Grade 1-2 adverse events. A pivotal Phase 2 registration trial comparing IBI363 to pembrolizumab in 180 treatment-naive patients is now underway, marking a significant advancement in melanoma treatment options.

Positive

• Strong efficacy with 23.3% confirmed objective response rate in traditionally treatment-resistant cold tumors
• Impressive 76.7% disease control rate across both mucosal and acral melanoma types
• Significant survival benefit with 14.8 months median overall survival and 61.5% 12-month OS rate
• Favorable safety profile with only 3.2% treatment discontinuation rate due to adverse events
• Initiated pivotal Phase 2 registration trial comparing IBI363 to established treatment (Keytruda)

Negative

• 29% incidence of Grade ≥3 treatment-related adverse events
• Limited patient sample size (31 patients) in Phase 1/2 studies

SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces the data from Phase 1 and Phase 2 clinical studies of IBI363, first-in-class PD-1/IL-2^α-bias bispecific antibody fusion protein, for the treatment of  "immune cold tumor" —immunotherapy-pretreated melanoma  (acral and mucosal subtypes) were orally presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. IBI363 has shown breakthrough efficacy in patients with heavily-treated melanoma subtypes - which are traditionally treatment-resistant "cold" tumors, and a pivotal registration trial for IBI363 is currently ongoing.

Innovent Biologics is conducting clinical studies in China, the United States, and Australia to explore the efficacy and safety of IBI363 for multiple tumor indications, including immune resistance, cold tumors, and front-line treatments. At this year's ASCO meeting, IBI363 reported encouraging Phase 1/2 clinical data in the first three indications explored—non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and melanoma—focusing on IO-resistant and cold tumors. The data comprehensively demonstrated the breakthrough clinical outcomes of IBI363 across these indications, from robust tumor response to long-term survival benefits. These findings provide strong support of the drug's novel mechanism of action translating effectively into clinical outcomes, and imply its potential for broader clinical development, offering new hope in areas of immunotherapy where treatment options remain limited.

A Phase 1/2 clinical study of PD-1/IL-2^α-bias bispecific antibody fusion protein (IBI363) in the treatment of advanced "cold" tumor subtypes (acral and mucosal) malignant melanoma

The data presented at this ASCO meeting are from two multi-center Phase 1 and 2 clinical studies (registration no.: NCT05460767, NCT06081920) designed to evaluate the efficacy and safety of IBI363 monotherapy in the treatment of advanced melanoma. As of April 7, 2025, a total of 31 patients with unresectable, locally advanced or metastatic acral and mucosal melanoma who had previously received immunotherapy were enrolled and treated at the dosage of 1 mg/kg Q2W, and 64.5% of them had ≥2 lines of prior treatment.

Breakthrough efficacy of IBI363 monotherapy has been achieved in patients with "immune-cold" melanoma, with notable durable response and prolonged survival benefit:

• In patients with at least one post-baseline tumor assessment (n=30), the confirmed objective response rate (cORR) was 23.3%, including 25.0% for mucosal type and 20.0% for acral type. The disease control rate (DCR) reached 76.7%, with 85.0% in mucosal type and 60.0% in acral type.
• In patients treated with 1 mg/kg Q2W with confirmed responses (n=7), a durable response was observed with a median duration of response (DoR) of 14.0 months and events of 42.9%.
• In patients treated with 1 mg/kg Q2W (n = 31) had a median progression-free survival (PFS) of 5.7 (2.7, 6.8) months, which was significantly longer than data from previous studies (PFS less than 3 months^[1] ). The median follow-up time was 14.7 months, the median overall survival (OS) was 14.8 (9.9, NC) months, and the median OS of patients with mucosal subtype was 19.3 (9.9, NC) months. The overall 12-month OS rate was 61.5%.
• In terms of safety, IBI363 was generally well tolerated. Among the subjects treated with 1 mg/kg Q2W (n = 31), the treatment-related adverse events (TRAEs) with an incidence > 30% were arthralgia, rash, and hyperthyroidism, most of which were Grade 1 or 2. The overall incidence of Grade ≥ 3 TRAEs was 29.0%, and only 3.2% of subjects discontinued treatment due to TRAEs. Overall safety was manageable, and no new safety risks were found.

	Acral+Mucosal  (1mg/kg Q2W) N=31
Confirmed ORR, % (95% CI)	23.3 (9.9, 42.3)
DCR, % (95% CI)	76.7 (57.7, 90.1)
Median PFS, months (95% CI)	5.7 (2.7, 6.8)
Median OS, months (95% CI)	14.8 (9.9, NC)
12-month OS rate, % (95% CI)	61.5 (39.8, 77.3)
Median OS follow-up, months	14.7

A pivotal Phase 2 registrational study of IBI363 in the treatment of advanced acral and mucosal malignant melanoma has been initiated

Innovent Biologics announced a trial in progress (TiP) . It is a randomized, open-label, multi-center Phase 2 study evaluating the efficacy and safety of IBI363 monotherapy compared to pembrolizumab (Keytruda®) in patients with unresectable, locally advanced or metastatic mucosal and acral melanoma who have not received prior systemic treatment. As the first pivotal registration trial of IBI363, this study is designed to directly compare IBI363 monotherapy with pembrolizumab in this patient population. A total of 180 patients are planned to be enrolled and randomized in a 1:1 ratio. The primary endpoint is progression-free survival (PFS) assessed by an Independent Review Committee (IRC).

The first patient was dosed in March 2025, marking a significant step in advancing IBI363's development in melanoma. Additional studies exploring IBI363 in combination therapies across other cancer types are also ongoing.

Professor Guo Jun from Peking University Cancer Hospital and the Principal Investigator of Melanoma Studies on IBI363 said: "Although melanoma is a relatively rare malignant tumor in China, it has a high mortality rate, and its incidence continues to rise each year. Historically, patients with melanoma who have not received immunotherapy have had a median PFS of only about 3 months, which highlights a significant unmet clinical need. Notably, non-cutaneous melanoma (especially mucosal melanoma) accounts for a large proportion of cases in China and is considered a 'cold tumor', typically unresponsive to traditional immunotherapy. In these cases, the response rate to PD-1 monotherapy is often below 15%, offering limited clinical benefit. More effective treatments are urgently needed^[2]. IBI363 addresses this challenge by transforming 'cold tumors' into 'hot tumors' through dual activation of the PD-1 and IL-2 pathways. The data presented in this study showed that IBI363 delivers significantly improved efficacy compared to previous studies in cold tumor subtypes and standard of care therapies, while maintaining a favorable safety profile. IBI363 has the potential to become a new standard in immunotherapy for malignant melanoma in China, providing a long-needed treatment option for patients with acral and mucosal malignant melanoma."

Dr. Zhou Hui, Senior Vice President of Innovent Biologics, said: "At present, there is a huge unmet clinical need for the treatment of unresectable, locally advanced or metastatic mucosal and acral melanoma in China. Approved PD-1 therapies have not substantially improved first-line outcomes in melanoma, and the clinical benefits remain limited^[3]. IBI363 is leading the evolution of next-generation immunotherapy. By leveraging a dual-mechanism of 'PD-1 blockade + IL-2 directed activation', IBI363 enhances T cell function and expands T cell populations to reshape the tumor immune microenvironment. IBI363 has shown excellent efficacy and safety results in the treatment of patients with immune-cold melanoma subtypes. A Phase 2 pivotal registrational study is currently underway. Positive results in patients with mucosal and acral melanoma are highly anticipated, offering hope for a more effective treatment option. Meanwhile, we are accelerating the global development of IBI363 across multiple tumor types, with the goal of making this innovative treatment accessible to patients around the world."

About Melanoma

Melanoma is a malignant tumor that develops from melanocytes. While it accounts for only 3% of all skin cancers, it has the highest mortality rate and is the most prone to metastasis. In China, both the incidence and mortality rates of melanoma are rising annually. Based on tumor location, melanoma is classified into cutaneous, acral, and mucosal subtypes. Melanoma in Chinese populations differs significantly from that in Caucasian populations in Europe and the United States with regard to pathogenesis, biological behavior, histological morphology, treatment methods, and prognosis^[4]. For patients with advanced cutaneous and acral melanoma with BRAF V600 mutation, a combination of BRAF and MEK inhibitors is the preferred treatment. For those without this mutation, chemotherapy combined with anti-angiogenic drugs is often considered as first-line treatment. Although pembrolizumab was approved in Sep. 2024 for first-line treatment of melanoma, the clinical benefit of PD-1 inhibitors in this setting remains modest. In second-line treatment, agents different from those used in the first line are generally preferred. For patients not previously treated with a PD-1 inhibitor, it can be considered as a second-line option. In advanced mucosal melanoma, median PFS for patients without prior immunotherapy is only about 3 months. Given the limited efficacy of current treatments for non-cutaneous melanomas, especially mucosal subtypes, which are more prevalent in China, there is an urgent need for more effective therapies.

About IBI363 (PD-1/IL-2 ^α-bias bispecific antibody fusion protein)

IBI363 is the world's first PD-1/IL-2^α-bias bispecific fusion protein independently developed by Innovent Biologics. It integrates two key functions: blockade of the PD-1/PD-L1 pathway and activation of the IL-2 signaling pathway. The IL-2 arm of IBI363 has been engineered to retain affinity for IL-2 Rα while reducing binding to IL-2Rβ and IL-2Rγ, thereby minimizing toxicity. The PD-1 binding arm enables simultaneous PD-1 blockage and selective delivery of IL-2. This differential targeting strategy exploits the fact that newly activated tumor-specific T cells co-express PD-1 and IL-2α, which allows for more precise and efficient targeting and activation of this T cell subset. IBI363 not only showed good anti-tumor activity in a variety of tumor-bearing pharmacological models but also showed prominent anti-tumor efficacy in PD-1 resistance and metastasis models.

Driven by urgent clinical needs, Innovent Biologics is conducting clinical studies in China, the United States, and Australia to assess the efficacy and safety of IBI363 across multiple tumor types. The first pivotal registration trial of IBI363 has been initiated for the treatment of mucosal and acral melanoma without immunotherapy.

IBI363 has been granted two fast track designations by the FDA for the treatment of advanced squamous non-small cell lung cancer and melanoma, respectively. IBI363 has also been granted Two Breakthrough Therapy Designations by the National Medical Products Administration (NMPA) for the treatment of advanced melanoma and squamous NSCLC.

About Innovent Biologics

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

For more information, please visit the company's website: www.innoventbio.com or the company's LinkedIn account.

Statement:

1. Innovent Biologics does not recommend the use of unapproved drugs/indications.

2. Ramucirumab injection (Ciranza®), selpercatinib capsules (Ritu®) and pirtobrutinib tablets (Capra®) were developed by Eli Lilly and Company

Forward-Looking Statement

The information in this press release may contain certain forward-looking statements. These statements are inherently risky and uncertain. The use of the words "anticipate," "believe," "predict," "expect," "intend" and similar expressions in connection with the Company are intended to identify forward-looking statements. The Company is under no obligation to continually update these predictive statements.

These forward-looking statements are based on the Company's management's existing views, assumptions, expectations, estimates, forecasts, and understandings of future matters at the time of the statements. These statements are not guarantees for future development and are subject to risks, uncertainties, and other factors, some of which are beyond the control of the Company and are difficult to predict. As a result, actual results may differ materially from those contained in such forward-looking statements as a result of future changes and developments in our business, competitive environment, political, economic, legal and social conditions.

The Company, its directors and employee agents have no obligation to (a) correct or update any forward-looking statements contained in this Website; and (b) any liability arising from the fact that any forward-looking statements cannot be realized or are rendered incorrect.

REFERENCES

[1].   Cui C, Yan X, Li B, et al.  Real-world clinical outcomes of anticancer treatments and prognostic factors in patients with advanced melanoma in China.  International Journal of Surgery Oncology.  2020; 5.  e97-e97.  doi:10.1097/IJ9.0000000000000097.

[2].   Cui C, Chen Y, Luo Z, et al.  Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study.  BMC Cancer.  2023;23(1):121.  Published 2023 Feb 6.  doi:10.1186/s12885-022-10473-y

[3].   Si L, Zhang X, Shu Y, et al.  A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151).Transl Oncol.  2019;12(6):828-835.  doi:10.1016/j.tranon.2019.02.007

[4].   Diagnostic and Therapeutic Guidelines for Melanoma (2022 Edition)

 

View original content:https://www.prnewswire.com/news-releases/asco-2025-oral-presentation-innovent-biologics-announces-updated-data-of-ibi363-first-in-class-pd-1il-2--bias-bispecific-antibody-fusion-protein-from-phase-1-and-2-clinical-studies-on-immunotherapy-treated-advanced-malignant--302470081.html

SOURCE Innovent Biologics

FAQ

What are the key efficacy results of IBI363 in treating melanoma?

IBI363 achieved a 23.3% confirmed objective response rate and 76.7% disease control rate in immunotherapy-pretreated melanoma patients, with median overall survival of 14.8 months

How does IBI363's safety profile look in clinical trials?

IBI363 showed manageable safety with mostly Grade 1-2 adverse events, 29% Grade ≥3 TRAEs, and only 3.2% treatment discontinuation rate

What makes IBI363 different from other melanoma treatments?

IBI363 is a first-in-class PD-1/IL-2α-bias bispecific antibody that uniquely transforms 'cold tumors' into 'hot tumors' through dual activation of PD-1 and IL-2 pathways

What is the current status of IBI363's clinical development?

A Phase 2 pivotal registration trial comparing IBI363 to pembrolizumab in 180 treatment-naive patients is ongoing, with first patient dosed in March 2025

How does IBI363 perform in different melanoma subtypes?

IBI363 showed efficacy in both mucosal (25% ORR, 85% DCR) and acral (20% ORR, 60% DCR) melanoma subtypes